Microbiome Editing
Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-15Jun 22, 2026
Gut-Brain Axis
The Gut–Brain Axis and the Future of Microbiome-Directed Mental Health Strategies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-22May 25, 2026
Microbiome
Zymo Research Launches Fecal Microbiome Discovery Grant to Enable the Next Breakthroughs in Human Health
Zymo Research Corp.
PR-04-26-10Apr 24, 2026
Microbiome
Innovating to Target the Microbiome for Human Health
Servatus
PAO-11-24-RTM-15Apr 8, 2025
Microbiome
Harnessing the Human Microbiome: 30 Years of Discovery and Innovation in Biopharma
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-02Mar 2, 2025
LBPs
Exploring the Microbiome with Servatus
Servatus
PAO-11-24-RTM-14Nov 18, 2024
Advanced Therapies
A New Vision for Progressing Advanced Therapies
Nathaniel Youndt
Recipharm Advanced Bio
PAO-10-24-CL-13Oct 25, 2024
Microbiome
Modifying the Gut Microbiome to Improve CAR-T, HSCT, and Other Therapeutic Responses
Stacy Burns-Guydish, Ph.D.
List Labs
PAO-10-23-CL-07-33Nov 1, 2023
Microbiome Therapeutic Innovation
Unleashing the Power of the Microbiome: Advancements, Challenges, and the Therapeutic Future
Stacy Burns-Guydish, Ph.D.; Gary Henderson
List Labs
PAO-03-23-CL-08Apr 4, 2023
Microbiome-Based CDMO
Expanding a Leadership Position in Microbiome-Based Contract Development and Manufacturing
Stacy Burns-Guydish, Ph.D.; Gary Henderson; Jonathan Yongwan Jo; Michael Kimble
List Labs
PAO-11-022-CL-13Dec 13, 2022
Diabetes Research
Composition of Gut Microbiome Predicts the Onset of Type 2 Diabetes
University of Turku
PR-M02-22-13Feb 16, 2022
Live Biotherapeutic Products
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
Aaron B. Cowley, Ph.D.; Nicole O'Brien, Ph.D.
Recipharm Advanced Bio
PAO-09-21-CL-11Sep 28, 2021
Live Biotherapeutic Products
Design Considerations for Live Biotherapeutic Product Facilities Working with Spore-Forming Bacteria
Aaron B. Cowley, Ph.D.; Judith Bodette; Brian Duffy
Recipharm Advanced Bio
PAO-06-21-CL-10Jun 25, 2021
Live Biotherapeutic Products
Framing the Narrative on CMC Development for Microbiome Therapeutics
Aaron B. Cowley, Ph.D.; Melanie Cerullo; Jeff Heiser
Recipharm Advanced Bio
PAO-06-21-CL-05Jun 14, 2021
Microbiome
Understanding the Link Between Gut Health and Disease
Dr. Sabine Hazan
ProgenaBiome
PTV-05-21-CL-004May 27, 2021
COVID-19 Impacts
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
Pharma's Almanac
PAO-03-21-NI-01Mar 16, 2021
Manufacturing Facility
Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and Closes Series B Equity Financing
Arranta Bio
PR-M03-21-002-1066Mar 8, 2021
Corporate Social Responsibility
Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity
Melanie Cerullo; Susan Surabian
Arranta Bio
PAP-Q4-20-CL-002Dec 9, 2020
The Future of Healthcare
How Does Arranta Bio Envision the Future of the Pharma/Biopharma Industry?
Arranta Bio
PAP-Q4-20-RT2-007Dec 9, 2020
Gene Editing
Enhancing Human Gut Tissue Models through Gene Editing
Scott Magness, Ph.D.
Altis Biosystems
PAO-11-20-CL-03Nov 30, 2020